The human Ether-a-go-go related gene (hERG) test is used to gauge hERG channel protein activity. For many years, Our company has been helping customers develop customized safety pharmacology evaluation services, especially hERG Tests, using a unique perspective to deliver better services faster, thus saving customers time and resources. We insist on being customer-centric and can customize the experimental design for your rare disease research project according to your specific requirements.
Overview of hERG
The ICH S7A and ICH S7B guidelines require that all compounds under consideration for investigational new drug (IND) applications be tested for hERG interaction in compliance with GLP principles. Human hERG is a potassium channel abundant in cardiomyocytes and is a key component of IKr currents and cardiac repolarization. Many compounds affect the activity of ion channels or transporters, thereby delaying ventricular repolarization and causing prolongation of the QT interval. Prolongation of the QT interval is associated with fatal ventricular tachyarrhythmias (Torsade de Pointes, TdP).
Electrophysiology for hERG Tests
The patch clamp technique represents the application of electrophysiology in hERG tests. The traditional patch-clamp technique (or Manual patch-clamp assay), which uses microelectrodes to record intracellular transmembrane potential, is recognized as the "gold standard" for ion channel research and is also the most accurate experimental method to measure ion channels. It is suitable for studying the mechanism of the interaction between compounds and ion channels. The emergence of some automated electrophysiological detection methods and devices, such as automated patch-clamp, has greatly improved the detection throughput compared with the traditional patch-clamp technology.
Our company has extensive experience in the design of hERG tests and has developed a variety of experimental methods to save more time for your project.
- Design of hERG Tests
As an integrated CRO, our company has the capabilities and resources to provide one-stop personalized custom service according to the client's specific needs.
|QPatch HTX or SyncroPatch 384PE
|CHO-hERG / HEK293-hERG
|Test Article Concentration
|Depending on solubility
|IC50 determination; Report
- Method of hERG Tests
Patch Clamp Assay
With rich experience in electrophysiological research, manual patch-clamp assay and automated patch-clamp assay are provided to support hERG testing.
Applying fluorescent dye and microplate reader technology to high-throughput screening of ion channel activity provides more possibilities for your rare disease therapy research.
Ligand Binding Assay
Radio-ligand binding assay and fluorescence polarization assay are provided to screen out potentially toxic to guide the selection of drug candidates.
Why Choose Us?
- Fast and cost-efficient workflow
- Timely project reporting and after-sales service
- Global reach and cutting-edge technology
- Superior data quality and fast turnaround
- Innovative and flexible solutions
- Reliable and trusted partner
As an integrated CRO, our company has extensive expertise in hERG tests for rare disease research. Whatever your specific requirements, we will work closely with you to develop a customized solution. We can quickly respond to the changing needs of your rare disease research projects. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
- Garrido, A., et al. "hERG toxicity assessment: Useful guidelines for drug design." European journal of medicinal chemistry 195 (2020): 112290.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.